Cite
HARVARD Citation
Diab, A. et al. (n.d.). 1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. Annals of oncology. p. . [Online].